RobertLReidMDFACP

Cancer Genetics/Cancer Risk Assessment, Genitourinary Oncology, Hematologic Oncology

Virginia Cancer Speciallists

Dr. Reid is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
8613 Route 29
Ste 200N
Fairfax, VA 22031
Phone+1 703-208-3155

Fax+1 703-280-9596

MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 1996 - 1997
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
University of MinnesotaResidency, Internal Medicine, 1987 - 1989
Rutgers Robert Wood Johnson Medical SchoolClass of 1987

PubMed

45 citations
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.
Deb Schrag, Tomasz M Beer, Charles H McDonnell 3rd, Lincoln Nadauld, Christina A Dilaveri
Lancet. 2023-10-07
46 citations
Soluble HTLV-I Tax1 protein stimulates proliferation of human peripheral blood lymphocytes.
S. J. Marriott, Paul F. Lindholm, Robert L. Reid, John N. Brady
The New Biologist. 1991-07-01
51 citations
Involvement of transcription factor YB-1 in human T-cell lymphotropic virus type I basal gene expression.
Fatah Kashanchi, Janet F. Duvall, Jürgen Dittmer, Alidad Mireskandari, Robert L. Reid
Journal of Virology. 1994-01-01

Clovis Oncology Highlights Rubraca® (Rucaparib) and Lucitanib Data at 2021 ASCO Annual MeetingMay 19th, 2021
Myriad’s myRisk Hereditary Cancer Test Finds Inherited Gene Mutations in More Than 12% of Prostate Cancer PatientsFebruary 8th, 2018